Guillain-Barré syndrome as clinical presentation of a recently acquired hepatitis C.
Diagnosis
Paralysis
Post-viral syndrome
Serology
Viremia
Journal
Journal of neurovirology
ISSN: 1538-2443
Titre abrégé: J Neurovirol
Pays: United States
ID NLM: 9508123
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
16
05
2023
accepted:
10
08
2023
revised:
27
07
2023
medline:
15
11
2023
pubmed:
30
8
2023
entrez:
30
8
2023
Statut:
ppublish
Résumé
About 40% of the Guillain-Barré syndrome (GBS) cases are associated with prodromal infections; occasionally, it has been associated to chronic hepatitis C or its reactivation. A 38-year-old man came to our attention after transaminase elevation occurred during recovery from GBS. All the possible causes of acute hepatitis were excluded except for the positivity of HCVRNA, and a diagnosis of new onset hepatitis C was made. Recalling patient history, we observed that (i) anti-HCV antibodies were negative and liver enzymes were normal 7 weeks before GBS onset; (ii) in the early stages of ICU admission, liver enzymes started to rise, but the elevation remained mild under steroid treatment; (iii) serum aminotransferase peak occurred 11 weeks after GBS onset; and (iv) HCV RNA was already significantly high when anti-HCV antibodies became positive, consistent with an acute hepatitis. Furthermore, anti-HCV seroconversion was likely delayed or blurred by steroids and immunoglobulin infusions. The interval of time between GBS onset and transaminase elevation compared with the patient clinical history allows us to establish a cause-effect relationship between the two diseases. All patients with GBS should be tested for hepatitis C, or its reactivation if already present, and followed up for an early diagnosis and treatment.
Identifiants
pubmed: 37646952
doi: 10.1007/s13365-023-01167-7
pii: 10.1007/s13365-023-01167-7
pmc: PMC10645643
doi:
Substances chimiques
Hepatitis C Antibodies
0
Transaminases
EC 2.6.1.-
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
640-643Informations de copyright
© 2023. The Author(s).
Références
Balwani M, Bawankule C, Ramteke V, Hepatitis Pasari A, C, (2018) virus directly acting antivirals and Guillain-Barré syndrome. Saudi J Kidney Dis Transpl 29(5):1237–1239. https://doi.org/10.4103/1319-2442.243969 . PMID: 30381528
doi: 10.4103/1319-2442.243969
pubmed: 30381528
Belbézier A, Bosseray A, Colombe B, Leroy V, Leclercq P, Bouillet L (2019) Guillain-Barré syndrome in AIDS patient secondary to an acute and confirmed hepatitis C virus. Presse Med 48(9):981–982. https://doi.org/10.1016/j.lpm.2019.08.004 . Epub 2019 Sep 19 PMID: 31543390
doi: 10.1016/j.lpm.2019.08.004
pubmed: 31543390
Cacoub P, Saadoun D (2021) Extrahepatic manifestations of chronic HCV infection. N Engl J Med 384(11):1038–1052. https://doi.org/10.1056/NEJMra2033539 . PMID: 33730456
doi: 10.1056/NEJMra2033539
pubmed: 33730456
Chlilek A, Roger C, Muller L, Carles MJ, Stephan R, Laureillard D, Lavigne JP, Lefrant JY, Sotto A (2019) Severe Guillain-Barré syndrome associated with chronic active hepatitis C and mixed cryoglobulinemia: a case report. BMC Infect Dis 19(1):636. https://doi.org/10.1186/s12879-019-4278-7.PMID:31315560;PMCID:PMC6637463
doi: 10.1186/s12879-019-4278-7.PMID:31315560;PMCID:PMC6637463
pubmed: 31315560
pmcid: 6637463
De Klippel N, Hautekeete ML, De Keyser J, Ebinger G (1993) Guillain-Barré syndrome as the presenting manifestation of hepatitis C infection. Neurology 43(10):2143. https://doi.org/10.1212/wnl.43.10.2143 . PMID: 8413983
doi: 10.1212/wnl.43.10.2143
pubmed: 8413983
Faccioli J, Nardelli S, Gioia S, Riggio O, Ridola L (2021) Neurological and psychiatric effects of hepatitis C virus infection. World J Gastroenterol 27(29):4846–4861. https://doi.org/10.3748/wjg.v27.i29.4846.PMID:34447230;PMCID:PMC8371503
doi: 10.3748/wjg.v27.i29.4846.PMID:34447230;PMCID:PMC8371503
pubmed: 34447230
pmcid: 8371503
Lacaille F, Zylberberg H, Hagège H, Roualdès B, Meyrignac C, Chousterman M, Girot R (1998) Hepatitis C associated with Guillain-Barré syndrome. Liver 18(1):49–51. https://doi.org/10.1111/j.1600-0676.1998.tb00126.x . PMID: 9548267
doi: 10.1111/j.1600-0676.1998.tb00126.x
pubmed: 9548267
Macleod WN (1987) Sporadic non-A, non-B hepatitis and Epstein-Barr hepatitis associated with the Guillain-Barré syndrome. Arch Neurol 44(4):438–442. https://doi.org/10.1001/archneur.1987.00520160068017 . PMID: 3030246
doi: 10.1001/archneur.1987.00520160068017
pubmed: 3030246
Malhotra P, Sanwariya Y (2022) HCV AND GUILLIAN-BARRE SYNDROME- A RARE ASSOCIATION. Int J Sci Appl Res 9(3):01–05. https://doi.org/10.5281/zenodo.6401446
Oh HW, Cha RR, Lee SS, Lee CM, Kim WS, Jo YW, Kim JJ, Lee JM, Kim HJ, Ha JC, Kim HJ, Kim TH, Jung WT, Lee OJ (2017) Comparing the clinical features and outcomes of acute hepatitis E viral infections with those of acute hepatitis A, B, and C infections in Korea. Intervirology 60(3):109–117. https://doi.org/10.1159/000480506 . Epub 2017 Nov 17 PMID: 29145204
doi: 10.1159/000480506
pubmed: 29145204
Rodríguez Y, Vatti N, Ramírez-Santana C, Chang C, Mancera-Páez O, Gershwin ME, Anaya JM (2019) Chronic inflammatory demyelinating polyneuropathy as an autoimmune disease. J Autoimmun 102:8–37. https://doi.org/10.1016/j.jaut.2019.04.021 . Epub 2019 May 6 PMID: 31072742
doi: 10.1016/j.jaut.2019.04.021
pubmed: 31072742
Shahrizaila N, Lehmann HC, Kuwabara S (2021) Guillain-Barré syndrome. Lancet 397(10280):1214–1228. https://doi.org/10.1016/S0140-6736(21)00517-1 . Epub 2021 Feb 26 PMID: 33647239
doi: 10.1016/S0140-6736(21)00517-1
pubmed: 33647239
Tse AC, Cheung RT, Ho SL, Chan KH (2012) Guillain-Barré syndrome associated with acute hepatitis E infection. J Clin Neurosci 19(4):607–608. https://doi.org/10.1016/j.jocn.2011.06.024 . Epub 2012 Jan 27 PMID: 22285113
doi: 10.1016/j.jocn.2011.06.024
pubmed: 22285113